Protection of hybridoma cells against apoptosis by a loop domain-deficient Bcl-xL protein

J Charbonneau1, E Gauthier

  • 1Cellular Biochemistry Research Laboratory , Department of Chemistry and Biochemistry, Laurentian University, Canada.

Cytotechnology
|November 13, 2008
PubMed

Insights

Modifying the Bcl-xL protein by removing its loop domain enhances its anti-apoptotic function in hybridoma cells. This improved protein boosts cell viability in stationary batch cultures.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biotechnology

Background:

  • Anti-apoptotic proteins of the Bcl-2 family are explored to enhance hybridoma cell viability.
  • The role of post-translational modifications, specifically loop domain presence, in Bcl-xL function within murine hybridomas remains unclear.

Purpose of the Study:

  • To investigate the anti-apoptotic properties of a Bcl-xL mutant lacking the loop domain (Bcl-xLΔ46-83).
  • To assess the impact of Bcl-xLΔ46-83 expression levels on hybridoma cell survival under stress conditions.

Main Methods:

  • Transfection of Sp2/0-Ag14 hybridoma cells with Bcl-xLΔ46-83.
  • Evaluation of cell resistance to L-glutamine deprivation and cycloheximide (CHX) cytotoxicity.
  • Analysis of cell viability and growth kinetics in stationary batch cultures.

Main Results:

  • Bcl-xLΔ46-83 conferred resistance to L-glutamine deprivation comparable to wild-type Bcl-xL.
  • Protection against CHX was dependent on the expression level of Bcl-xLΔ46-83.
  • The Bcl-xLΔ46-83 mutant significantly prolonged hybridoma cell viability in batch culture, proportional to its expression level.

Conclusions:

  • Removal of the loop domain enhances the anti-apoptotic activity of Bcl-xL in hybridoma cells.
  • The modified Bcl-xL protein (Bcl-xLΔ46-83) shows potential for improving hybridoma cell culture stability.

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...